Onconetix Inc (ONCO): Rasio kapitalisasi marang pendapatan

The development of prostate cancer platforms is in its early stages, driving a linear increase in R&D expenses for Onconetix, Inc. (ONCO). A patent moat for biomarker tests in the US serves to protect its market share. Analyzing the price-to-sales ratio per share on GURU.Markets, we note that the 1.90 mark reflects the latest data, assisting management in commercializing innovations in urology.

ONCO Onconetix Corp: Rasio rega marang pendapatan ing interval 13.04.2024 - 14.11.2026

Rincian analitis perusahaan Onconetix Inc (ONCO)

- kuotasi saiki lan rata-rata prakiraan nilai:

Rega bursa Onconetix Inc|ONCO - Bagan rega target

- data kapitalisasi bursa:

Kapitalisasi pasar Onconetix Corporation|ONCO - Nilai Perusahaan

- rincian valuasi buku bisnis:

Nilai Akuntansi saben Saham Onconetix|ONCO - Nilai Buku Perusahaan|Koefisien Nilai Pasar marang Nilai Buku onconetix.gcs-web.com|ONCO - Aset Agregat Perusahaan

- statistik kawajiban utang lan likuiditas:

- data bathi bisnis lan rasio investasi:

ONCO - Penghasilan resik|Penghasilan resik sing dikarepake Onconetix, Inc.|ONCO - Pangali P/E|Kapitalisasi marang proyeksi bathi Onconetix Corporation|ONCO - Rasio rega marang bathi tumrap wutah|Nilai perusahaan marang bathi operasional sadurunge panyusutan Onconetix Corporation|ONCO - Bathi operasional EBITDA|Bathi resik saben saham sajrone 12 wulan pungkasan Onconetix|ONCO - Bathi resik saben saham sajrone 12 wulan pungkasan|Owah-owahan bathi resik saben saham taun-ka-taun sajrone rolas wulan pungkasan onconetix.gcs-web.com|ONCO - Wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi resik saben saham ing taun ngarep Onconetix, Inc.

- data total pendapatan lan volume dodolan:

ONCO - Pendapatan perusahaan|Prakiraan pendapatan perusahaan Onconetix|ONCO - Multiplikator P/S|Multiplikator forward rega marang pendapatan Onconetix

Ringkesan analitik perusahaan:Onconetix

The P/S ratio determines the market value of one dollar of revenue, allowing an investor to assess the degree of an asset's overvaluation and timely identify a trend reversal. Analysis of the price-to-sales ratio reflects the monetization efficiency of R&D projects at Onconetix, Inc. (ONCO), linking the company's capitalization to the actual sales volume of its innovative diagnostic systems for combating prostate cancer.

Perusahaan pesaing